Identification of primary care patients at risk of nonadherence to antidepressant treatment by Åkerblad, Ann-Charlotte et al.
© 2008 Åkerblad et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Preference and Adherence 2008:2 379–386 379
ORIGINAL RESEARCH
Identiﬁ  cation of primary care patients at risk
of nonadherence to antidepressant treatment
Ann-Charlotte Åkerblad1
Finn Bengtsson2
Margareta Holgersson3
Lars von Knorring1
Lisa Ekselius1
1Department of Neuroscience, 
Psychiatry, Uppsala University 
Hospital, Uppsala University, Uppsala, 
Sweden; 2Division of Clinical 
Pharmacology, Medicine and Care, 
Faculty of Health Sciences, Linköping 
University, Linköping, Sweden; 
3Quintiles AB, Uppsala, Sweden
Correspondence: Ann-Charlotte Åkerblad
Department of Neuroscience, Psychiatry, 
Uppsala University Hospital, Uppsala 
University, SE-751 85 Uppsala, Sweden
Email ann-charlotte.akerblad@uaspsyk.uu.se
Introduction: Poor adherence to antidepressant treatment is common, and results in increased 
disability and costs. Several factors are thought to inﬂ  uence patients’ ability and willingness 
to adhere. So far, however, consensus is lacking regarding patient characteristics that predict 
nonadherence. The purpose of this study was to identify predictors of nonadherence to antide-
pressant treatment that can be ascertained at treatment start.
Method: The present study used data from a randomized controlled trial with the main objective 
of studying the effect of two different compliance-enhancing programs on treatment adherence 
and treatment response in 1031 primary care patients with major depression. In this study, logis-
tic regression analyses were performed to examine patient- and illness-related characteristics 
potentially associated with nonadherence.
Results: Nonadherence to antidepressant treatment was predicted by age under 35 or over 
64 years, presence of personality disorder, sensation-seeking personality traits, substance abuse, 
and absence of concomitant medications.
Conclusion: Certain patient- and illness-related characteristics may imply an increased risk 
of nonadherence to antidepressant treatment. Giving special attention to subjects with such 
characteristics may improve adherence.
Keywords: unipolar depression, antidepressant, adherence, compliance, SSRI, predictors
Introduction
Adherence to antidepressant medication has been recognized as an important factor 
regarding optimal treatment outcome (Frank et al 1992; Melﬁ   et al 1998; Åkerblad et al 
2006; Gopinath et al 2007). Nonadherence behavior includes premature or temporary 
discontinuation of medication, erratic intake or intake of a lower or higher dose than 
prescribed. Despite treatment recommendations, it is probable that less than half of 
primary care patients diagnosed with depression and prescribed antidepressants take 
their medication for six to nine months or longer (Demyttenaere et al 2001; Cantrell 
et al 2006; Olfson et al 2006). In a large retrospective study of 22,947 patients start-
ing treatment with selective serotonin reuptake inhibitors (SSRIs), the six-month 
nonadherence rate was approximately 57% as measured by the length of treatment 
and medication possession ratio (Cantrell et al 2006). When the patients’ partial or 
erratic adherence to treatment is taken into account, the proportion of patients with 
adequate treatment probably decreases further. Overall, nonadherence to antidepres-
sant drug treatment has been found to vary from 10% to 60% (Lingam and Scott 2002; 
Åkerblad et al 2003). Another important aspect of antidepressant treatment is clinic 
visits (Demyttenaere 2003). A relation between adherence to the clinic visit-schedule 
and outcome has been shown (Åkerblad et al 2003).
The ability of patients to follow prescribed treatment is often hindered by different 
factors including social and economic circumstances, the health care system, the 
provider, the disease and its treatment, and patient-related factors (Demyttenaere 
1997; Osterberg and Blaschke 2005). Identifying subjects at risk of nonadherence Patient Preference and Adherence 2008:2 380
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right from the start of treatment increases the possibility of 
intervening with the aim of improving adherence. This early 
identiﬁ  cation of patients at risk of nonadherence might thus 
improve the chance of optimal treatment and a better overall 
outcome. It cannot be ruled out that premature dropout, non-
adherence and nonattendance are, at least in part, predicted 
by different characteristics as suggested by Demyttenaere 
and colleagues (1998). However, regardless of the nature 
of nonadherence to treatment behavior, a relation between 
adherence and outcome has been shown (Åkerblad et al 
2003). Research on easily identiﬁ  ed predictors of nonadher-
ence to antidepressant drug treatment such as demographics, 
sociodemographics, illness characteristics and personality 
is limited, rather inconclusive, and involves small numbers 
of patients (Pampallona et al 2002; Demyttenaere 2003; 
Cohen et al 2004). In the present study an attempt was made 
to identify predictors of nonadherence to antidepressants 
that can be ascertained by the physician before initiation of 
treatment. We hypothesized that demographics, depression 
characteristics, and personality are of importance regarding 
poor adherence.
Subjects and methods
Study sample
Data for this study were obtained from a randomized, con-
trolled, multicenter study, the Swedish Long-term Implica-
tions of Compliance Enhancing programs study (SLICE) 
(Åkerblad et al 2003, 2006). The main objective of that 
investigation was to study the effect of two different compli-
ance-enhancing programs on treatment adherence and treat-
ment response to sertraline during a 24-week period. Patients 
in the Compliance Enhancement Program (CP) group were 
provided with written educational material covering typical 
issues and recovery patterns associated with successful treat-
ment of major depression (Mundt et al 2001; Kutcher et al 
2002). The goal of the program is to maximize the therapeutic 
outcome by encouraging adherence to treatment. A starter kit 
was given to the patient when treatment began, and a total of 
ﬁ  ve different letters were mailed to the patient during the ﬁ  rst 
18 weeks of treatment. In the Therapeutic Drug Monitoring 
(TDM) group, blood samples from the patients were collected 
for immediate analysis of sertraline and the major metabolite, 
desmethylsertraline, at weeks 4 and 12. The physician respon-
sible for treatment and the TDM laboratory communicated 
via standardized request forms. By means of TDM, dose 
optimization for individual patients, including monitoring 
of adherence, side effects and drug–drug interactions, can be 
accomplished (Burke and Preskorn 1999; Bengtsson 2004). 
The two intervention groups were compared with a control 
group in which patients were treated in accordance with the 
general practitioners’ clinical routine. Neither of the two 
interventions tested improved the adherence rate signiﬁ  cantly 
as compared to the control group (Åkerblad et al 2003). The 
study methods and the results for the initial 24 weeks were 
previously presented in detail (Åkerblad et al 2003).
The SLICE-study was conducted in primary care with 
general practitioners managing the treatment. A total of 93 
general practitioners included patients in the open-labeled 
study. In order to avoid carrying over some of the features 
of the different adherence interventions between treatment 
groups, a cluster randomization design was used. Thus, the 
general practitioners, and not the patients, were randomized 
to the three treatment groups, and each practitioner included 
patients in one treatment group only. The randomization 
was done in a consecutive way based on a computerized 
randomization list.
To assess adherence and clinical outcome, visits at the 
outpatient department were conducted at baseline, and at 
4, 12, and 24 weeks. Data were collected by the general 
practitioners on case report forms (CRFs) designed for this 
study. During the study, concordance between the medical 
records and the case report forms was monitored.
To be included in the study, patients had to fulﬁ  ll the 
criteria for major depression according to the DSM-IV (APA 
1994) and have a clinical indication for treatment with an 
SSRI. Male and female patients 18 years of age or older 
were included if they gave their written informed consent 
to participate in the study. The only exclusion criteria were 
contraindications to sertraline.
The study was conducted in accordance with the Dec-
laration of Helsinki (Revised in South Africa in 1996). 
It was approved by the regional ethics committees at the 
Swedish universities in Umeå, Uppsala, Örebro, Stockholm, 
Linköping, and Gothenburg.
Assessments
Measurement of nonadherence
In the present study, a conservative deﬁ  nition of adherence 
was used (Åkerblad et al 2003) requiring: (a) measurable 
serum levels of sertraline and/or desmethylsertraline at 
weeks 4, 12 and 24 (ie, blood samples were taken in all 
three groups, but during the study the results were disclosed 
only in the TDM-group); (b) self-reported assurance that 
the patient had taken sertraline as prescribed. (The patient 
was asked by the general practitioner if he/she had taken the 
medication as prescribed. Based on the patient’s answer the Patient Preference and Adherence 2008:2 381
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general practitioner recorded a “Yes” or a “No” on the CRF); 
and (c) scheduled visits performed within the stipulated time 
frames (ie, 4 ± 1, 12 ± 4, and 24 ± 2 weeks). Accordingly, 
patients discontinuing sertraline treatment prematurely, 
withdrawing from the study, or not fulﬁ  lling one or more of 
the three adherence criteria speciﬁ  ed above were classiﬁ  ed 
as nonadherent at 24 weeks. As adherence is then deﬁ  ned 
and used as a dichotomous variable, adherence vs nonadher-
ence, patients with nonadherence are all patients who do not 
fulﬁ  ll the adherence criteria, thus comprising a somewhat 
heterogeneous group.
Personality disorders and personality traits
The presence of personality disorders was assessed using the 
DSM-IV and ICD-10 Personality Questionnaire (DIP-Q). This 
is a 135-item true/false self-report questionnaire designed 
to measure personality disorders according to DSM-IV 
and ICD-10. The DIP-Q has been validated by comparing 
questionnaire-based results with those from a semi-structured 
interview in a clinical sample of 138 individuals (Ottoson 
et al 1998). In the present study only DSM-IV personality 
disorders were assessed, and anti-social personality was 
excluded.
Personality traits were assessed by the Swedish 
Universities Scales of Personality (SSP) (Gustavsson et al 
2000). The SSP comprises 91 items divided into 13 scales 
with seven items in each. Each item is presented as a 
statement with a four-point response format, ranging from 1, 
“does not apply at all” to 4, “applies completely”. The SSP 
mean scores were transformed into normative T-scores 
with means of 50 and standard deviations of 10 based on a 
Swedish gender-stratiﬁ  ed nonpatient sample (Gustavsson 
et al 2000). A maximum likelihood factor analysis with 
orthogonal rotation (varimax) was performed to iden-
tify factors with an eigenvalue 1. Similar to the factor 
analysis of the normative data (Gustavsson et al 2000), the 
correlations of the 13 scales yielded a three-factor model. 
The scales Somatic Trait Anxiety, Psychic Trait Anxiety, 
Stress Susceptibility, Lack of Assertiveness, Detachment, 
Embitterment, Trait Irritability, and Mistrust loaded highly 
on the ﬁ  rst factor, hereafter referred to as Neuroticism. The 
second factor consisted of Social Desirability (negative 
loading), Verbal Trait Aggression, Trait Irritability, and 
Physical Trait and will be referred to as Aggressiveness. 
Impulsiveness and Adventure Seeking loaded highly on the 
third factor, termed Sensation Seeking. The corresponding 
scores from the three factors were subsequently used in the 
statistical analyses.
Quality of life
Health-related quality of life was assessed at baseline by the 
EuroQol questionnaire – 5 dimensions (EQ-5D) (EuroQoL 
Group 1990). The EQ-5D is a standardized and widely used 
generic instrument comprised of two parts: a visual analogue 
scale, and ﬁ  ve questions that assess the respondent’s health 
according to ﬁ  ve distinct dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression. 
Each dimension has three different levels: no problems, some/
moderate problems, and extreme problems. Combined, these 
dimensions and levels make up 243 unique theoretical health 
states, to which quality of life index scores between –0.59 
and 1 (full health), also referred to as societal valuation, were 
assigned using a standardized tariff based on the general UK 
population (Dolan et al 1996). The results from the visual 
analogue scale were not used in the present study.
Severity of depression
The severity of depression was assessed by means of the 
Montgomery–Åsberg Depression Rating Scale (MADRS) 
(Montgomery and Åsberg 1979) and the Clinical Global 
Impression – Severity scale (CGI-S) (Guy 1976). Before 
the start of the trial, a weighted kappa of 0.7 for inter-rater 
reliability of MADRS ratings was obtained.
Potentially associated predictors
Predictor variables potentially associated with adherence 
to antidepressants were selected based on earlier research 
and clinical experience (Frank et al 1992; Lin et al 1995; 
Demyttenaere et al 1998; Ekselius et al 2000; Cohen et al 
2004). The variables were grouped into patient-related char-
acteristics and illness-related characteristics. The variables 
are shown in Tables 1 and 2.
Statistics
All statistical analyses were performed using SAS® software 
(version 8.2; SAS Institute, Cary, NC). Data presented in this 
report are based on the intention-to-treat (ITT) population.
In summary, the statistical analyses in the present study 
included bivariate evaluation of the relationship between 
nonadherence and each potential predictor, followed by a 
stepwise logistic regression analysis.
Prior to the bivariate analyses, all continuous variables 
were inspected with regard to conformity with a linear gradient. 
Based on the ﬁ  nding of a U-formed relation with nonadherence 
seen with increasing age when plotting the proportion of non-
adherent patients for different age groups, the variable age was 
categorized into three groups (18–34 years, 35–64 years, and Patient Preference and Adherence 2008:2 382
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65 years and older). In addition, due to a nonlinear relationship, 
“age at ﬁ  rst depression” and “concomitant medication” were 
categorized in the subsequent analyses.
The bivariate analyses included all patient- and illness-
related characteristics potentially associated with non-
adherence as described above. Testing for association 
with nonadherence was performed using chi-square tests 
(categorical variables) or t-tests (continuous variables). 
Variables with a p-value of 0.25 or less were included 
in logistic regression analyses (Hosmer et al 2000) with 
nonadherence as the dependent variable (SAS® PROC 
LOGISTIC). The variables were included in order of statis-
tical signiﬁ  cance starting with the variable with the lowest 
p-value. In order to adjust for the interventions in the 
analyses, this variable was included in the model although it 
did not meet the p  0.25 criterion. The inclusion of interven-
tion group in the model was expected to reduce the possible 
bias of pooling the three treatment groups.
In the regression analyses only variables remaining sta-
tistically signiﬁ  cant (p  0.05) were retained in the model. 
Table 1 Associations between patient-related characteristics and adherence
Variable Adherent Nonadherent p
Gender, n (%) 
  Female 308 (41.6) 433 (58.4) 0.291
  Male 110 (37.9) 180 (62.1)
Age, n (%) 
  Low: 18–34 yrs 54 (26.7) 148 (73.3) 0.00011
  (reference) Mid: 35–64 yrs 319 (45.3) 385 (54.7)
 High:  65 yrs 45 (36.0) 80 (64.0)
Living status, n (%) 
Married/cohabiting 273 (43.1) 360 (56.9) 0.0311
Other 145 (36.4) 253 (63.6)
Number of children 0–18 yrs living 
at home, mean (SD)3
0.71 (1.08) 0.78 (1.11) 0.332
Education, n (%) 
  Primary school 131 (42.3) 179 (57.7) 0.921
  (reference) High school 188 (41.2) 268 (58.8)
  University 86 (40.6) 126 (59.4)
Employment, n (%) 
  – yes 297 (42.8) 397 (57.2) 0.0351
  – other 121 (35.9) 216 (64.1)
Student, n (%) 
  – yes 19 (29.7) 45 (70.3) 0.0681
  – other 399 (41.3) 568 (58.7)
Unemployment, n (%) 
  – yes 30 (34.1) 58 (65.9) 0.201
  – other 388 (41.2) 555 (58.8)
Retired, n (%) 
  – yes 46 (36.2) 81 (63.8) 0.291
  – other 372 (41.2) 532 (58.9)
Early retirement, n (%) 
  – yes 30 (44.1) 38 (55.9) 0.531
  – other 388 (40.3) 575 (59.7)
Nicotine use, n (%) 
  – yes 150 (37.2) 253 (62.8) 0.0821
  – no 268 (42.7) 360 (57.3)
Neuroticism factor score*, mean (SD) 69.4 (9.91) 71.2 (10.9) 0.00712
Aggressiveness factor score*, mean (SD) 20.4 (8.83) 21.8 (9.91) 0.0222
Sensation seeking factor score*, mean (SD) 48.2 (8.90) 50.5 (8.75) 0.00012
Notes: *Each estimated factor score is computed as a linear combination of the unstandardized values of the variables that are factored; 1Chi-square test; 2t-test; 3missing data 
for one adherent patient and 30 nonadherent patients.
Abbreviation: SD, standard deviation.Patient Preference and Adherence 2008:2 383
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Table 2 Associations between illness-related characteristics and adherence
Variable Adherent Nonadherent p
Baseline characteristics
Total MADRS-score, mean (SD) 26.5 (5.65) 27.0 (5.97) 0.121
CGI-S-score, mean (SD) 4.16 (0.78) 4.22 (0.79) 0.231
QoL societal valuation, mean (SD)3 0.61 (0.27) 0.60 (0.27) 0.531
Personality disorder, n (%)
  – yes 107 (31.9) 228 (68.1) 0.00012
  – no 310 (46.5) 357 (53.5)
Concomitant medications, n (%)
  – yes 31 (44.1) 420 (55.9)
0.00022
  – no 87 (31.1) 193 (68.9)
Psychiatric history
Previous depression, n (%)
  – yes 251 (42.0) 346 (58.0)
0.252
  – no 167 (38.5) 267 (61.5)
No of previous depression episodes
(if any), mean (SD)4 3.24 (3.88) 3.62 (4.87) 0.291
Age at ﬁ  rst depression episode, n (%)
  0–29 yrs 103 (34.2) 198 (65.8)
0.00732   30–64 yrs (ref) 287 (44.2) 362 (55.8)
  65 yrs 28 (34.6) 53 (65.4)
Hospitalized for depression, n (%)
  – yes 32 (45.1) 39 (54.9) 0.422
  – no 386 (40.2) 574 (59.8)
Previous antidepressant drug treatment, n (%) 
  – yes 182 (43.3) 238 (56.7) 0.132
  – no 236 (38.6) 375 (61.4)
Successful prev. antidepressant treatment, n (%) 
  – yes 90 (46.6) 103 (53.4)
0.0562
  – no 328 (39.1) 510 (60.9)
Suicide attempt(s) in the past, n (%)
  – yes 26 (35.1) 48 (64.9)
0.332
  – no 392 (41.0) 565 (59.0)
Other psychiatric illness (past), n (%)
  – yes 50 (44.3) 63 (55.7)
0.402
  – no 368 (40.1) 550 (59.9)
Other psych. illness (present), n (%)
  – yes 40 (38.1) 65 (61.9)
0.592
  – no 378 (40.8) 548 (59.2)
Substance abuse (past/present), n (%)
  – yes 20 (25.0) 60 (75.0)
0.00322
  – no 398 (41.8) 553 (58.2)
Depression in family, n (%)
  – yes 111 (38.7) 176 (61.3)
0.452
  – no 307 (41.3) 437 (58.7)
Notes: 1t-test; 2Chi-square test; 3Missing data for 13 adherent patients and 33 nonadherent patients; 4n = 248 for adherent patients and 341 for nonadherent patients.
Abbreviation: SD, standard deviation.Patient Preference and Adherence 2008:2 384
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Odds ratios (OR) were estimated with 95% confidence 
intervals for these variables. The resulting logistic models were 
re-estimated by means of a generalized estimating equations 
model (Hardin and Hilbe 2002), using SAS® PROC GENMOD 
to adjust for the effects of the cluster randomization design.
Based on the protocol, all patients were requested to com-
plete the DIP-Q and SSP questionnaires at baseline, but 70 and 
73 patients, respectively, did not do so. In order to reduce the 
number of missing observations, imputation of the results 
from the personality assessment after 12 weeks was done for 
41 subjects regarding the presence of any personality disorder, 
and for 42 subjects regarding the personality traits.
Results
Study population
The ITT population included 1031 patients (71.9% females, 
28.1% males) with a mean age of 48.4 years and a mean 
MADRS score at baseline of 26.8. The demographic proﬁ  le 
of the study population was described in a previous report 
(Åkerblad et al 2003) In the regression analyses, data from 
33 patients were deleted due to missing values.
Nonadherence to treatment
During the 24-week study period, 249 patients (24.1%) 
discontinued treatment with sertraline and/or withdrew from 
the study. Of the 782 patients completing 24 weeks of treat-
ment, 364 were classiﬁ  ed as nonadherent; 141 (38.7%) did not 
complete the questionnaires, 78 (21.4%) did not have mea-
surable serum levels, and 219 (60.2%) did not adhere to the 
appointment schedule. Thus, 613 (59.5%) of the 1031 patients 
did not fulﬁ  ll the pre-deﬁ  ned adherence criteria.
Patient- and illness-related characteristics
Bivariate associations between patient- and illness-related 
characteristics and adherence are presented in Table 1 and 
Table 2, respectively. A total of 18 variables had a p-value 
of 0.25 or less and were accordingly included in the primary 
step-wise logistic regression analysis. After controlling for 
intervention group, the logistic regression analysis revealed 
that patients in the younger age group (18–34 years) and 
patients in the older age group (65 years and older), with 
the middle age group as reference, were more likely to 
be nonadherent (Table 3). Patients with no concomitant 
medication, all medications regardless of underlying con-
dition included, were also more likely to be nonadherent. 
The analysis also showed that the presence of personality 
disorder, sensation-seeking personality traits and substance 
abuse each predicted nonadherence.
Goodness-of-ﬁ  t
Goodness-of-ﬁ  t was evaluated using Pearson’s residual chi-square 
test. The null hypothesis of good ﬁ  t (small discrepancies between 
observed and predicted values according to the model) could not 
be rejected, indicating a high goodness-of-ﬁ  t. The test results 
were: chi-square = 7.53 (df = 15), and p = 0.94.
Discussion
Predictors of poor adherence to antidepressant treatment can 
be a useful resource in identifying those patients who are most 
in need of interventions to improve adherence (Osterberg and 
Blaschke 2005). However, previous research is limited and has 
most often involved small numbers of patients (Pampallona et al 
2002; Demyttenaere 2003). In the present study, low age as well 
as high age, presence of personality disorder, sensation-seeking 
personality traits, substance abuse, and absence of concomitant 
medication were shown to be independent predictors.
Patient-related characteristics
In our study, both young age and old age were shown to predict 
poor adherence. The results of earlier studies, where age was 
included as a potential predictor of adherence/nonadherence 
to antidepressants, are somewhat conflicting. In several 
studies, no relation between age and adherence was found 
(Frank et al 1992; Lin et al 1995; Bull et al 2002). However, 
in line with our ﬁ  nding, Demyttenaere and colleagues (1998) 
reported that young age was a predictor of premature dropout 
from antidepressant drug treatment. Our ﬁ  nding that high 
age predicts nonadherence is contradicted by the results of 
Sirey and colleagues (2001) showing that age over 60 years 
was a predictor for adherence. In previous research in other 
therapeutic areas, high age has not consistently been shown 
to predict either adherence or nonadherence, although some 
potentially age-related factors such as living situation and 
polypharmacy have been shown to be related to nonadherence 
Table 3 Logistic regression estimates (odds ratios) for the effect 
of patient- and illness-related characteristics on nonadherence1
OR 95% CI
Age 18–35 years vs 35–64 years 1.80 1.29–2.53
65 years vs 35–64 years 1.60 1.01–2.53
Alcohol/drug abuse (past and/or present) 1.80 1.07–3.05
Absence of concomitant medication 1.79 1.32– 2.44
Presence of personality disorder 1.43 1.10– 1.87
Sensation-seeking personality traits 
factor score (unit = 1 SD)
1.25 1.10–1.43
Note: 1Controlled for intervention group.
Abbreviations: CI, conﬁ  dence interval; OR, odds ratio; SD, standard deviation.Patient Preference and Adherence 2008:2 385
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(Lorenc and Branthwaite 1993; Salzman 1995). In a recent 
primary care study of older adults by Mackin and Areán 
(2007), cognitive functioning and depression severity were 
identiﬁ  ed as predictors of missed appointments but not of 
treatment adherence.
Consistent with earlier ﬁ  ndings from our research group, we 
found that nonadherence was predicted by sensation-seeking 
personality traits (Ekselius et al 2000). This ﬁ  nding is under-
standable, since individuals who are impulsive, nonplanning, 
and who avoid routines and have a need for change may not 
ﬁ  nd it easy or signiﬁ  cant to adhere to daily medication regimens 
and follow-up visits. The ﬁ  nding is also in line with another 
study reporting a strong association between novelty seeking 
personality traits and early discontinuation from clinical trials 
in patients with anxiety disorders (Wingerson et al 1993).
Illness-related characteristics
A somewhat unexpected ﬁ  nding in the present study was that 
patients with no concomitant medication were more likely to 
be nonadherent. Previous research on the impact of polyphar-
macy on adherence has mainly focused on the elderly. In a 
review by Vik and colleagues (2004) the authors concluded 
that “an increased number of medications may adversely 
affect adherence, although ﬁ  ndings have not been consistent”. 
A reasonable explanation for our ﬁ  nding may be that it is easier 
for patients with no other prescriptions to forget to take their 
medication. Another tentative explanation is that depressed 
patients with no other diseases, and consequently no other 
medications, have less insight into their illness and less belief 
in the beneﬁ  ts of treatment (especially when they start feeling 
better). Recent research has shown that the perceived stigma 
associated with mental illness and the individual patient’s 
views about the illness and medication play an important role 
in adherence to treatment for depression (Brown et al 2005; 
Brook et al 2006; Mackin and Arean 2007). Furthermore, 
skepticism about antidepressants has been shown to predict 
early discontinuation of SSRIs (Aikens et al 2005). These 
ﬁ  ndings are also in line with the extrapolated Health Belief 
Model, which states that individuals perform a cost/beneﬁ  t 
analysis in which they determine if the beneﬁ  ts of treatment 
outweigh the costs (adverse effects, social stigma, cost of 
treatment, etc.) (Becker and Maiman 1975).
Substance abuse predicted nonadherence to antidepressant 
medication in the present study. In a recent study on medica-
tion adherence in ﬁ  rst episode schizophrenia, alcohol abuse 
at baseline and previous drug abuse were shown to predict 
nonadherence (Kamali et al 2006). Further, in a study of 
psychiatrist-reported treatment nonadherence among patients 
in routine psychiatric care, substance abuse was shown to 
predict problems with adherence (Compton et al 2005).
Research concerning the impact of personality pathology 
on antidepressant adherence is sparse and somewhat con-
ﬂ  icting. The present study revealed that the presence of a 
personality disorder increased the risk of nonadherence. In 
accord with this, Compton and colleagues (2005) found that 
a personality disorder diagnosis was associated with poor 
adherence. Analogously, Sirey and colleagues (2001) reported 
that medication adherence was predicted by the absence of 
personality pathology assessed by the Inventory of Interper-
sonal Problems. However, in a long-term study of prophylaxis 
in recurrent depression by Frank and colleagues (1992), no 
differences were observed between adherent and nonadherent 
patients with respect to the presence of personality disorder 
determined using the Personality Assessment Form.
Methodological considerations
A limitation of this study is that the SLICE study was not 
designed with the primary aim of conﬁ  rming predictors of 
nonadherence. Moreover, it was not designed to explore the 
impact of emotional and psychological factors (eg, perceived 
stigma and the individual’s views about the illness and medi-
cation), and such factors have recently been shown to affect 
adherence to antidepressant therapy (Sirey et al 2001; Brown 
et al 2005; Brook et al 2006). A tentative explanation regard-
ing our results is that subjects in young or old age groups, 
with personality psychopathology, substance abuse or no 
other medications, present with such obstacles to adherence 
to a greater extent than those who are adherent.
A potential drawback of the study may be the classiﬁ  cation 
of adherence versus nonadherence. The present study used a 
pre-deﬁ  ned deﬁ  nition of adherence; thus, patients who discon-
tinued medication or withdrew from the study, regardless of 
the reason, were all classiﬁ  ed as nonadherent. This approach 
might have resulted in an overestimation of nonadherence. 
Furthermore, no distinction was made between different types 
of nonadherent behavior. On the other hand, the aim of the study 
was to explore nonadherence, regardless of the reason, and to 
identify patient and illness characteristics that can be ascertained 
at treatment start. The ability to identify potential treatment 
failures, and then to give these patients special attention and take 
relevant action right from the start of treatment, may increase 
adherence to medication and the chance of recovery.
Conclusion
This study shows that certain patient- and illness-related 
characteristics may imply an increased risk of nonadherence Patient Preference and Adherence 2008:2 386
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to antidepressant treatment in primary care. Giving special 
attention to patients with such characteristics may improve 
adherence.
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